Medical technology giant Becton Dickinson & Co. announced Thursday it has reached a settlement of $22 million to end four class action lawsuits against the firm accusing the company of attempting to monopolize the hypodermic needle market. Specifically, members of the class action claimed BD of squeezing competitors out of the market by offering steep discounts on bundled hospital equipment products so long as hospitals agreed to buy the majority of their needles from BD. Further, BD was accused of giving company stock to group purchasing organizations, which determine prices set for hospitals. Court documents allege that such agreements were anticompetitive, violated antitrust law, raised prices and reduced innovation. The company announced the settlement along with its third-quarter earnings report. BD says the settlement cut share prices by 7 cents.
Full Content: North Jersey
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI